Genotoxicity of tamoxifen citrate and 4-nitroquinoline-1-oxide in the wing spot test of Drosophila melanogaster

Mutagenesis

Volumn 19, Issue 3, 2004, Pages 187-193

  Heres Pulido, M Eugenia ^a   Dueñas García, Irma ^a   Castañeda Partida, Laura ^a   Sánchez García, Antonio ^a   Contreras Sousa, Martha ^a   Durán Díaz, Ángel ^a   Graf, Ulrich ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; ANTIESTROGEN; CARCINOGEN; DNA; N METHYL DEXTRO ASPARTIC ACID; TAMOXIFEN CITRATE; XENOBIOTIC AGENT;

ANIMAL CELL; ARTICLE; CHRONIC TOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA ADDUCT; DOSE RESPONSE; DROSOPHILA MELANOGASTER; DRUG DETOXIFICATION; DRUG STRUCTURE; FORELIMB; GENE MUTATION; GENETIC CROSS; GENETIC MARKER; GENETIC RECOMBINATION; GENOTOXICITY; HETEROZYGOSITY; LARVAL DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; SOMATIC CELL; STANDARD; TOXICITY TESTING; XENOBIOTIC METABOLISM;

4-NITROQUINOLINE-1-OXIDE; ANIMALS; BREAST NEOPLASMS; CARCINOGENS; DROSOPHILA MELANOGASTER; FEMALE; HUMANS; LARVA; NITROSAMINES; QUINOLONES; TAMOXIFEN; WING;

DROSOPHILA MELANOGASTER; MELANOGASTER; RODENTIA;

EID: 2942553504     PISSN: 02678357     EISSN: None     Source Type: Journal    
DOI: 10.1093/mutage/geh020     Document Type: Article

References (44)

1. Batiste-Alentorn,M., Xamena,N., Creus,A. and Marcos,R. (1995) Genotoxic evaluation of ten carcinogens in the Drosophila wing spot test. Experientia, 51, 73-76.
2. Bhimani,R.S., Troll,W., Grunberger,D. and Frenkel,K. (1993) Inhibition of oxidative stress in HeLa cells by chemopreventive agents. Cancer Res., 53, 4528-4533.
3. Boocock,D.J., Brwon,K., Gibbs,A.H., Sanchez.E., Turteltaub,K.W. and White,I.N.H. (2002) Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis, 23, 1897-1901.
4. Clark,A.M. (1982) The use of larval stages of Drosophila in screening for some naturally occurring mutagens. Mutat. Res., 92, 89-97.
5. Crewe,H.K., Notley,L.M., Wunsch,R.M., Lennard,M.S. and Gillam,E.M.J. (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug. Metab. Dispos., 30, 869-874.
6. Danielson,P.B., MacIntyre,R.J. and Fogleman,J.C. (1997) Molecular cloning of a family of xenobiotic-inducible drosophilid cytochrome P450s: evidence for involvement in host-plant allelochemical resistance. Proc. Natl Acad Sci. USA, 94, 10797-10802.
7. Danielson,P.B., Foster,J.L.M., McMahill,M.M., Smith,M.K. and Fogleman,J.C. (1998) Induction by alkaloids and phenobarbital of Family 4 cytochrome P450s in Drosophila: evidence for involvement in host plant utilization. Mol. Gen. Genet., 259, 54-59.
8. Dehal,S.S. and Kupfer,D. (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res., 57, 3402-3406.
9. Desai,P.B., Nallani,S.C., Sane,R.S., Moore,L.B., Goodwin,B.J., Buckley,D.J. and Buckley,A.R. (2002) Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab. Dispos., 30, 608-612.
10. Dunkov,B.C., Guzov,V.M., Mocelin,G., Shotkoski,F., Brun,A., Amichot,M., Ffrench-Constant,R.H. and Feyereisen,R. (1997) The Drosophila cytochrome P450 gene Cyp6a2: structure, localization, heterologous expression and induction by phenobarbital. DNA Cell Biol., 16, 1345-1356.
11. El-Kattan,A.F., Asbill,C.S., Kim,N. and Michniak,B.B. (2001) The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities. Int. J. Pharm., 215, 229-240.
12. Frei,H. and Würgler,F.E. (1988) Statistical methods to decide whether mutagenicity test data from Drosophila indicate a positive, negative, or inconclusive result. Mutat. Res., 203, 297-308.
13. Frei,H. and Würgler,F.E. (1995) Optimal experimental design and sample size for the statistical evaluation of data from somatic mutation and recombination tests (SMART) in Drosophila. Mutat. Res., 334, 247-258.
14. Frei,H. and Würgler,F.E. (1996) Induction of somatic mutation and recombination by four inhibitors of eukaryotic topoisomerases assayed in the wing spot test of Drosophila melanogaster. Mutagenesis, 11, 315-325.
15. Frei,H., Clements,J., Howe,D. and Würgler,F.E. (1992) The genotoxicity of the anti-cancer drug mitoxantrone in somatic and germ cells of Drosophila melanogaster. Mutat. Res., 279, 21-33.
16. Frölich,A. and Würgler,F.E. (1989) New tester strains with improved bioactivation capacity for the Drosophila wing spot test. Mutat. Res., 216, 179-187.
17. Graf,U. and van Schaik,N. (1992) Improved high bioactivation cross for the wing somatic mutation and recombination test in Drosophila melanogaster. Mutat. Res., 271, 59-67.
18. Graf,U., Würgler,F.E., Katz,A.J. Frei,H., Juon,H., Hall,C.B. and Kale,P.G. (1984) Somatic mutation and recombination test in Drosophila melanogaster. Environ. Mutagen., 6, 153-188.
19. Graf,U., Frei,H., Kägi,A., Katz,A.J. and Würgler,F.E. (1989) Thirty compounds tested in the Drosophila wing spot test. Mutat. Res., 222, 359-373.
20. Graf,U., Abraham,S.K., Guzmán-Rinón,J. and Würgler,F.E. (1998) Antigenotoxicity studies in Drosophila melanogaster. Mutat. Res., 402, 203-209.
21. Hällström,I., Blanck,A. and Atuma,S. (1984) Genetic variation in cytochrome P-450 and xenobiotic metabolism in Drosophila melanogaster. Biochem. Pharmacol., 33, 13-20.
22. Hayatsu,H., Inada,N., Kafutani,T., Arimoto,S., Negishi,T., Mori,K., Okuda,T. and Sakata,I. (1992) Suppression of genotoxicity of carcinogens by (-)-epigallocatechin gallate. Prev. Med., 21, 370-376.
23. IARC (1996) Tamoxifen. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, no. 66, Some Pharmaceutical Drugs. IARC, Lyon, pp. 253-365.
24. Kawai,K. (1998) Enhancement of the DNA damaging activity of N-nitrosodimethylamine by di(2-ethylhexyl)phthalate in somatic cells in vivo of Drosophila melanogaster. Biol. Pharm. Bull., 21, 579-582.
25. Kaya,B., Creus,A., Velazquez,A., Yaniko,A. and Marcos,R. (2002) Genotoxicity is modulated by ascorbic acid. Studies using the wing spot test in Drosophila melanogaster. Mutat. Res., 520, 93-101.
26. Mirzayans,R., Bashir,S., Murray,D. and Paterson,M.C. (1999) Inverse correlation between p53 protein levels and DNA repair efficiency in human fibroblast strains treated with 4-nitroquinoline 1-oxide: evidence that lesions other than DNA strand breaks trigger the p53 response. Carcinogenesis, 20, 941-946.
27. Moorthy,B., Sriram,P., Randerath,E. and Randerath,K. (1997) Effects of cytochrome P450 inducers on tamoxifen genotoxicity in female mice in vivo. Biochem. Pharmacol., 53, 663-669.
28. Negishi,T., Nakano,H., Kitamura,A., Itome,C., Shiotani,T. and Hayatsu,H. (1994) Inhibitory activity of chlorophyllin on the genotoxicity of carcinogens in Drosophila. Cancer Lett., 83, 157-164.
29. Notley,L.M., De Wolf,C.J., Wunsch,R.M., Lancaster,R.G. and Gillam,E.M. (2002) Bioactivation of tamoxifen by recombinant human cytochrome p450 enzymes. Chem. Res. Toxicol., 15, 614-622.
30. Osborne,M.R., Hardcastle,I.R. and Phillips,D.H. (1997) Minor products of reaction of DNA with alpha-acetoxytamoxifen. Carcinogenesis, 18, 539-543.
31. Poirier,M.C. and Schild,L.J. (2003) Meeting Report. The genotoxicity of tamoxifen: extent and consequences, Kona, Hawaii, January 23, 2003. Mutagenesis, 18, 395-399.
32. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis, 15, 2087-2094.
33. Rodríguez-Arnaiz,R., Soto,P.O., Oyarzun,J.C. and Graf,U. (1996) Analysis of mitotic recombination induced by several mono- and bifunctional alkylating agents in the Drosophila wing spot test. Mutat. Res., 351, 133-145.
34. Saner,C., Weibel,B., Würgler,F.E. and Sengstag,C. (1996) Metabolism of promutagens catalyzed by Drosophila melanogaster CYP6A2 enzyme in Saccharomyces cerevisiae. Environ. Mol. Mutagen., 27, 46-58.
35. Sharpe,C.R., Collet,J.-P., Belzile,E., Hanley,J.A. and Boivin,J.-F. (2002) The effects of tricyclic antidepressants on breast cancer risk. Br. J. Cancer, 86, 92-97.
36. Shibutani,S., Shaw,P.M., Suzuki,N., Dasaradhi,L., Duffel,M.W. and Terashima,I. (1998) Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts. Carcinogenesis, 19, 2007-2011.
37. Shibutani,S., Reardon,J.T., Suzuki,N. and Sancar,A. (2000) Excision of tamoxifen-DNA adducts by the human nucleotide excision repair system. Cancer Res., 60, 2607-2610.
38. Spanó,M.A., Frei,H., Würgler,F.E. and Graf,U. (2001) Recombinagenic activity of four compounds in the standard and high bioactivation crosses of Drosophila melanogaster in the wing spot test. Mutagenesis, 16, 385-394.
39. Stiborová,M., Bosek-Dohalská,L., Hodek,P., Mráz,J. and Frei,E. (2002) New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen Arch. Biochem. Biophys., 40, 41-49.
40. Styles,J.A., Davies,A., Davies,R., White,I.N. and Smith,L.L. (1997) Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from dosed rats and in human lymphoblastoid cells transfected wih human P450 cDNAs (MCL-5 cells). Carcinogenesis, 18, 303-313.
41. Thackray,V.G., Young,R.H., Hooper,J.E. and Nordeen,S.K. (2000) Estrogen agonist and antagonist action on the human oestrogen receptor in Drosophila. Endocrinology, 141, 3912-3915.
42. van Schaik,N. and Graf,U. (1991) Genotoxicity evaluation of five tricyclic antidepressants in the wing somatic mutation and recombination test in Drosophila melanogaster. Mutat. Res., 260, 99-104.
43. van Schaik,N. and Graf,U. (1993) Structure-activity relationships of tricyclic antidepressants and related compounds in the wing somatic mutation and recombination test of Drosophila melanogaster. Mutat. Res., 286, 155-163.
44. White,I.N.H. (1999) The tamoxifen dilemma. Carcinogenesis, 20, 1153-1160.